Investors and Partners
We have built the ultimate adaptable diagnostic platform. Adaptability powers the only platform that anyone will ever need.
The Panacea Value Proposition
For pharma, biotechs and CROs, sur solutions include quantitative high throughput of patient derived organoids for drug discovery and analysis of rare and precious human primary material and quantitative single cell analysis.
For diagnostics companies and those specialising in health preservation and longevity our solutions embrace point of care with 3-minute readout and high levels of multiplex for capillary blood, serum, urine, saliva and swabs. Contexts range from distributed diagnostics to clinic bedside concierge health and retail.
Panacea in Numbers
$0M
Invested in FreeFlow™ up to end 2025
0
Markers monitored on FreeFlow™ by end of 2025 including proteins, nucleic acids and small molecules
8-0
Weeks turnaround for novel assay development with partners
0%
CV in 304-patient clinical study
0%
AUC for 304-patient clinical study
0.99-0
Correlation of FreeFlow™ POC for CRP in serum against gold standard Siemens, Roch and Abbott laboratory platforms
Panacea Welcomes
Partners and customers looking for a white label platform solution for their biomarker panel or for translation of existing approved markers from centralised testing to POC or distributed diagnostic environments.
Pharma and Biotechs with analytical challenges in precision medicine.
Enquiries from investors and strategic partners with an interest accelerating the growth of our business together.
Adaptability creates opportunity. Our applications lab and applications team can adapt FreeFlow™ to meet your needs.
Information Request
Ask us for our latest data.
Data Request
"*" indicates required fields